GFM
IOVA icon

GF Fund Management’s Iovance Biotherapeutics IOVA Stock Holding History

GF Fund Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$36.3K Sell
8,716
-199
-2% -$756 ﹤0.01% 432
2026
Q1 		$31.3K Buy
8,915
+1,085
+14% +$3.47K ﹤0.01% 453
2025
Q4 		$21.4K Buy
7,830
+45
+0.6% +$104 ﹤0.01% 502
2025
Q3 		$16.9K Sell
7,785
-20
-0.3% -$47 ﹤0.01% 508
2025
Q2 		$13.4K Hold
7,805
– – ﹤0.01% 538
2025
Q1 		$26K Buy
7,805
+1,405
+22% +$7.25K ﹤0.01% 476
2024
Q4 		$47.4K Buy
+6,400
New +$59.3K ﹤0.01% 394

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

GF Fund Management's IOVA Position: Q2 2026 in Review

GF Fund Management reduced its Iovance Biotherapeutics (IOVA) stake by 2.2% in Q2 2026, selling an estimated $756 and leaving 8,716 shares worth $36.3K. The position accounts for ﹤0.01% of the portfolio, ranked #432.

GF Fund Management first reported a position in IOVA in Q4 2024 and has held it in 7 quarters since. The position peaked at $47.4K in Q4 2024. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • GF Fund Management held 8,716 shares of Iovance Biotherapeutics worth $36.3K as of Q2 2026.
  • GF Fund Management sold 199 Iovance Biotherapeutics shares in Q2 2026, an estimated $756.
  • Iovance Biotherapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #432 holding.
  • GF Fund Management first reported a position in Iovance Biotherapeutics in Q4 2024 and has held it in 7 quarters since.
  • GF Fund Management's Iovance Biotherapeutics position peaked at $47.4K in Q4 2024.
  • 292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.